Clinical Trials Logo

Lymphoma, Non-Hodgkin clinical trials

View clinical trials related to Lymphoma, Non-Hodgkin.

Filter by:

NCT ID: NCT00185679 Terminated - Clinical trials for Non-Hodgkin's Lymphoma (NHL)

Haploid Allogeneic Transplant Using the CliniMACS System

Start date: November 2001
Phase: Phase 2
Study type: Interventional

To assess the proportion of patients with donor neutrophil engraftment within 30 days of allogeneic transplant. To assess the incidence of acute GvHD during the first 100 days after transplantation.

NCT ID: NCT00183976 Terminated - Clinical trials for Non-Hodgkin's Lymphoma

Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas

Start date: April 2005
Phase: Phase 2
Study type: Interventional

This study is for patients who have been treated before and either the treatment did not work or the lymphoma has come back.

NCT ID: NCT00183950 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy

Start date: March 2000
Phase: Phase 1/Phase 2
Study type: Interventional

This study is for patients with non-hodgkin's lymphoma or chronic lymphocytic leukemia, which has failed to shrink or has returned after previous treatment with chemotherapy. The purpose of this study is to find out whether patients with these types of cancer will have their tumor shrunk after treatment with a drug called Noscapine. The second purpose is to see what are the side effects of this drug. This drug is being used as an over-the-counter cough suppressor in Europe and Japan, but has also shown to be effective against cancer.

NCT ID: NCT00147485 Terminated - Neoplasms Clinical Trials

A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer

Start date: December 2004
Phase: Phase 1
Study type: Interventional

AG-024322 may work in cancer by stopping cancer cells from multiplying. AG-024322 is and intravenous drug from a new class of drugs call cyclin-dependent kinase (CDK inhibitors). This research study is the first time that AG-024322 will be given to people.

NCT ID: NCT00143884 Terminated - Multiple Myeloma Clinical Trials

Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood

Start date: March 2000
Phase: Phase 2
Study type: Interventional

This research project will focus on whether it is safe and effective to rely on donor cells to prevent relapse of leukemia, lymphoma, or other blood cancer after bone marrow stem cell transplant.

NCT ID: NCT00141700 Terminated - Clinical trials for Lymphoma, Non-Hodgkin's

Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma

Start date: March 2003
Phase: Phase 2
Study type: Interventional

This study is being conducted to determine the safety, side effects, and response to a combination of an established high-dose chemotherapy regimen, stem cell support and Rituximab (which is a form of immunotherapy).

NCT ID: NCT00133302 Terminated - Clinical trials for Non-Hodgkin's Lymphoma

Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)

Start date: February 1999
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to investigate the clinical benefit of the dose intensified regimen, Bi-CHOP in comparison to standard CHOP for advanced intermediate or high grade non-Hodgkin's lymphoma (NHL).

NCT ID: NCT00126243 Terminated - Clinical trials for AIDS Related Lymphoma

Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin’s Lymphoma

Start date: January 1999
Phase: Phase 2
Study type: Interventional

Most treatment procedures in AIDS-related lymphomas disclose a relatively poor outcome for patients with low response rates, high number of relapses and AIDS events. The addition of rituximab to the standard regimen - CHOP could improve the outcome of these patients. The aim of the trial is to evaluate the safety and efficacy of rituximab when added to the CHOP regimen in patients with newly diagnosed AIDS-related non-Hodgkin lymphoma.

NCT ID: NCT00126191 Terminated - Burkitt Lymphoma Clinical Trials

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

Start date: July 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to learn more about how well a chemotherapy regime including rituximab works in treating patients with Burkitt or atypical Burkitt lymphoma.

NCT ID: NCT00120198 Terminated - Clinical trials for Non-Hodgkin's Lymphoma

Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

Start date: March 2005
Phase: Phase 2
Study type: Interventional

Currently there is no one standard of care for older patients with Non-Hodgkin's Lymphoma (NHL). The study will examine the tolerability and feasibility to the combination of Cyclophosphamide, Pegylated Liposomal Doxorubicin, Vincristine, Prednisone (CDOP) plus Rituximab.